ÂÜÀòÂÒÂ×

Galen Miley has a wealth of experience in the field of chemistry. In 2009, they began their academic career as a Chemistry major at Reed College, where they served as an Advanced Organic Chemistry Teaching Assistant and Research Assistant. Theirthesis project under Dr. Aaron Nilsen involved designing and implementing a novel route to acid-sensitive quinolone derivatives for the treatment of malaria. In 2012, they were a Researcher at Portland State University and Reed College under Drs. David Griffiths and Erik Sanchez, where they collaborated in the development and investigation of laboratory ball lightning model. In 2013, they were a Chemist at Portland VA Research Foundation and Oregon Health Sciences University under Dr. Michael Riscoe, where they developed new 4-(1H)quinolone compounds to treat and prevent malaria, cancer and toxoplasmosis. From 2014 to 2019, they were a Graduate Student and PPG Graduate Fellow at Northwestern University under Drs. Richard Silverman and Neil Kelleher, where they designed and implemented photoaffinity probe target ID in a murine melanoma model and conducted mass spec-based discovery and total synthesis of novel natural products for evaluation of bioactivity and target elucidation. Most recently, they have been a Postdoctoral Researcher at Eindhoven University of Technology in the Brunsveld Lab since 2019 and a Scientist at Ambagon Therapeutics since 2020.

Galen Miley's education history includes a Doctor of Philosophy (Ph.D.) from Northwestern University in Organic Chemistry (2014-2019), a Bachelor of Arts (BA) from Reed College in Chemistry (2009-2013), and a Diploma from Barrie School (2005-2009).